Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

• Verfasst von: Hahne, Stefanie [VerfasserIn]
• Verfasst von: Kunath, Frank [VerfasserIn]
• Verfasst von: Coles, Bernadette [VerfasserIn]
• Verfasst von: Dräger, Désirée Louisê [VerfasserIn]
• Verfasst von: Krabbe, Laura-Maria [VerfasserIn]
• Verfasst von: Dersch, Rick [VerfasserIn]
• Verfasst von: Kilian, Samuel [VerfasserIn]
• Verfasst von: Jensen, Katrin [VerfasserIn]
• Verfasst von: Dahm, Philipp [VerfasserIn]
• Verfasst von: Meerpohl, Jörg J. [VerfasserIn]
• Titel: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer
• Titelzusatz: abridged summary of the Cochrane review
• Verf.angabe: Stefanie Schmidt, Frank Kunath, Bernadette Coles, Desiree Louise Draeger, Laura-Maria Krabbe, Rick Dersch, Samuel Kilian, Katrin Jensen, Philipp Dahm, Joerg J. Meerpohl
• E-Jahr: 2020
• Jahr: Jun 29, 2020
• Umfang: 6 S.
• Fussnoten: Gesehen am 29.10.2020
• Titel Quelle: Enthalten in: Investigative and clinical urology
• Ort Quelle: Seoul : The Korean Urological Association, 2016
• Jahr Quelle: 2020
• Band/Heft Quelle: 61(2020), 4, Seite 349-354
• ISSN Quelle: 2466-054X
• DOI: doi:10.4111/icu.2020.61.4.349
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1737354748

Abstract

People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour. Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain. Although several systematic reviews and meta-analyses have been conducted on this topic, it still remains unclear what the optimal treatment dose and schedule might be, as well as the question of which people benefit most from one or the other agent.